Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market
Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with revenue projections soaring to $4.3B by 2030. Read more here.
Medindia15h
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES-  SCLC   - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...
El País in English17h
Kerstin Noëlle Vokinger: ‘New cancer therapies are being approved for patient groups not included in clinical trials’
Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...
HealthDay on MSN22h
Tivozanib Has Efficacy in Advanced Renal Cell Carcinoma Post-ICI Therapy
For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...